Some investors asked Linuo Pharmaceutical on an interactive platform. In the TGV semiconductor glass substrate circuit, Germany's SCHOTT used the rolled borosilicate glass route, Corning used the aluminum-borosilicate glass route, and the company's technical route was compared to SCHOTT. Facing AI advanced packaging application scenarios, what differentiated core performance advantages does the company's rolled borosilicate glass have compared to aluminum-borosilicate glass systems, and what kind of competitive opportunities will this route bring to the company? Linuo Pharmaceuticals replied that glass substrates are still in their early stages and have not yet entered the mass scale application stage. Various technology routes have advantages and disadvantages, and enterprises throughout the industry chain are still needed to collaborate to jointly promote the progress of the industry. The company is currently still in the sample delivery phase. The company has used glass substrates as one of the company's key projects, but no revenue has been generated so far, so please be aware of investment risks.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.